# Buzz Radar Client Portfolio
# Updated November 2025

# Client tiers based on revenue and strategic importance
client_tiers:
  major: "£100k+ annual value or strategic importance"
  growth: "£30k-100k with expansion potential"
  pilot: "£30k pilots with upsell opportunity"
  prospect: "In pipeline, not yet closed"

clients:

  # MAJOR CLIENTS
  - name: "ViiV Healthcare"
    tier: "Major"
    relationship_status: "Active - Multiple Programs"
    parent_company: "GSK/Pfizer/Shionogi JV"

    current_contracts:
      - program: "Digital Listening Program"
        annual_value: 650000
        status: "At Risk"
        risk_factors:
          - "Internal restructuring moved budget control"
          - "Competing vendor-friendly teams now involved"
        notes: "Need to shift from defensive positioning"

    pipeline_opportunities:
      - name: "ViiV Comms Congress"
        value: 45000
        stage: "Verbal Agreement"
        likelihood: 8
      - name: "ViiV DOL CX"
        value: 100000
        stage: "Proposal Being Reviewed"
        likelihood: 5
      - name: "ViiV International Region V2"
        value: 250000
        stage: "Build Proposal"
        likelihood: 3

    key_contacts:
      - name: "Alejandro Potes"
        role: "Congress lead"
      - name: "Mary Andrews"
        role: "DOL decision maker"
      - name: "Hugo Barbosa"
        role: "International region"

    total_potential: 1045000  # Current + pipeline
    account_owner: "Patrick Charlton"

  - name: "GSK"
    tier: "Major"
    relationship_status: "Active - Growing"

    current_contracts:
      - program: "Blenrep"
        annual_value: 250000
        status: "Renewal Pending"
        renewal_stage: "Proposal Being Reviewed"
        likelihood: 9
        expected_close: "2025-11-30"
        decision_maker: "Ale"
        notes: "Critical renewal - high confidence"

    pipeline_opportunities:
      - name: "GSK Medical Patient Engagement - Oncology"
        value: 250000
        max_value: 500000
        stage: "Warm Lead"
        likelihood: 7
        expected_close: "2026-01-31"
        notes: "Large oncology program - high priority"
      - name: "GSK Sci Coms BRIANN Pilot"
        value: 30000
        stage: "Warm Lead"
        likelihood: 3

    key_contacts:
      - name: "Ale"
        role: "Blenrep & Oncology lead"

    total_potential: 780000
    priority: "Critical"

  - name: "Johnson & Johnson MedTech"
    tier: "Major"
    relationship_status: "Active - Rapidly Expanding"

    pipeline_opportunities:
      - name: "JJMT US Engagement"
        value: 100000
        stage: "Procurement"
        likelihood: 10
        expected_close: "2025-11-01"  # Overdue
        notes: "In procurement - needs chasing"
      - name: "JJMT US Change Management"
        value: 90000
        stage: "Build Proposal"
        likelihood: 5
      - name: "JJMT Europe"
        value: 175000
        stage: "Warm Lead"
        likelihood: 5
      - name: "JJMT Vision"
        value: 175000
        stage: "Warm Lead"
        likelihood: 5

    key_contacts:
      - name: "Gabriel Medeiros"
        role: "Primary contact - all programs"

    total_pipeline: 540000
    notes: "Strong relationship, multiple divisions engaged"
    priority: "High"

  - name: "Bayer"
    tier: "Major"
    relationship_status: "Active - Growing"

    pipeline_opportunities:
      - name: "Bayer Nubeqa SOV 25/26"
        value: 50000
        stage: "Procurement"
        likelihood: 10
        expected_close: "2025-10-01"  # Overdue
        notes: "In procurement - should have closed"
      - name: "Bayer DOL"
        value: 100000
        stage: "Proposal Being Reviewed"
        likelihood: 5
        expected_close: "2025-11-30"
        last_contact: "2025-11-14"
      - name: "Bayer Nubeqa SOV 26/27"
        value: 50000
        stage: "Warm Lead"
        likelihood: 7
        expected_close: "2026-06-30"

    key_contacts:
      - name: "Carolyn Austring"
        role: "Nubeqa program"
      - name: "Jim Gawley"
        role: "DOL program"

    total_pipeline: 200000
    account_owner: "Patrick Charlton"

  # GROWTH CLIENTS
  - name: "Abbott"
    tier: "Growth"
    relationship_status: "Active"

    pipeline_opportunities:
      - name: "Abbott CES"
        value: 20000
        stage: "Procurement"
        likelihood: 5
        expected_close: "2025-12-12"

    key_contacts:
      - name: "Simon Goldberg"
        role: "Decision maker"

  - name: "CTA (Consumer Technology Association)"
    tier: "Growth"
    relationship_status: "Active Partner"

    current_contracts:
      - program: "CES Partnership"
        annual_value: 30000
        status: "Won"
        notes: "CES 2026 confirmed"

    key_contacts:
      - name: "nvidovich@cta.tech"
        role: "Primary contact"

  - name: "Ferring Pharmaceuticals"
    tier: "Growth"
    relationship_status: "New - Closing"

    pipeline_opportunities:
      - name: "Ferring BRIANN Pilot"
        value: 30000
        expansion_potential: 245000
        stage: "Verbal Agreement"
        likelihood: 8
        expected_close: "2025-11-30"

    key_contacts:
      - name: "Jennifer Cleall"
        role: "Decision maker"

    notes: "New logo win - high expansion potential"

  # PROSPECTS - NEW LOGOS
  - name: "Gilead Sciences"
    tier: "Prospect"
    relationship_status: "New Business"

    pipeline_opportunities:
      - name: "Gilead Command Centre Congress"
        value: 125000
        stage: "Warm Lead"
        likelihood: 5

    notes: "New logo opportunity - congress command centre"

  - name: "Jazz Pharmaceuticals"
    tier: "Prospect"
    relationship_status: "New Business"

    pipeline_opportunities:
      - name: "Jazz Pharmaceuticals"
        value: 100000
        stage: "Warm Lead"
        likelihood: 3
        expected_close: "2025-12-31"

    key_contacts:
      - name: "Loucif"
        role: "Primary contact"

  - name: "Merck"
    tier: "Prospect"
    relationship_status: "New Business"

    pipeline_opportunities:
      - name: "Merck BRIANN Pilot"
        value: 30000
        expansion_potential: 245000
        stage: "Warm Lead"
        likelihood: 5
        expected_close: "2025-12-31"

    key_contacts:
      - name: "Jason Yau"
        role: "Decision maker"

  # COLD LEADS - BRIANN PILOT PROSPECTS
  - name: "UCB"
    tier: "Prospect"
    relationship_status: "Cold Lead"
    pipeline_value: 30000
    expansion_potential: 240000
    notes: "BRIANN pilot opportunity"

  - name: "Chugai Pharmaceutical"
    tier: "Prospect"
    relationship_status: "Cold Lead"
    pipeline_value: 30000
    expansion_potential: 240000
    notes: "BRIANN pilot opportunity"

  - name: "CSL Behring"
    tier: "Prospect"
    relationship_status: "Cold Lead"
    pipeline_value: 30000
    expansion_potential: 240000
    notes: "BRIANN pilot opportunity"

  - name: "Vertex Pharmaceuticals"
    tier: "Prospect"
    relationship_status: "Cold Lead"
    pipeline_value: 30000
    expansion_potential: 240000
    notes: "BRIANN pilot opportunity"

  - name: "BioMarin"
    tier: "Prospect"
    relationship_status: "Cold Lead"
    pipeline_value: 30000
    expansion_potential: 240000
    notes: "BRIANN pilot opportunity"

# Portfolio analysis
portfolio_analysis:

  concentration:
    viiv_percentage: 50  # Of current revenue
    risk_level: "High"
    target_max_single_client: 30
    mitigation: "Actively diversifying with JJMT, Bayer, and new logos"

  revenue_at_risk:
    viiv_dlp: 650000
    gsk_blenrep: 250000  # Renewal pending
    total_at_risk: 900000

  growth_opportunities:
    jjmt_expansion: 540000
    gsk_oncology: 500000
    new_logos: 355000  # Gilead, Jazz, Merck
    briann_pilots: 150000  # 5 cold leads x £30k
    briann_expansion: 1200000  # If all pilots expand

  client_count:
    active_revenue: 4  # ViiV, GSK, Abbott, CTA
    closing_soon: 3  # Ferring, JJMT, Bayer
    prospects: 8  # Gilead, Jazz, Merck, UCB, Chugai, CSL, Vertex, BioMarin
